Human γδ T lymphocytes induce robust NK cell-mediated antitumor cytotoxicity through CD137 engagement

Blood

Volumn 116, Issue 10, 2010, Pages 1726-1733

  Maniar, Amudhan ^a   Zhang, Xiaoyu ^a,b   Lin, Wei ^a   Gastman, Brian R ^a   Pauza, C David ^a   Strome, Scott E ^a   Chapoval, Andrei I ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND DENTAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD137 ANTIGEN; CD137 LIGAND; CD86 ANTIGEN; IMMUNOGLOBULIN G; KLRK1 PROTEIN, HUMAN; LYMPHOCYTE ANTIGEN RECEPTOR; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY K; OX40 LIGAND; TNFSF4 PROTEIN, HUMAN;

ARTICLE; CELL COMMUNICATION; CELL CULTURE; CELL LINE; CELL STRAIN K 562; CULTURAL ANTHROPOLOGY; CYTOLOGY; CYTOTOXICITY; CYTOTOXICITY TEST; FLOW CYTOMETRY; HUMAN; IMMUNOLOGY; METABOLISM; NATURAL KILLER CELL; NEOPLASM; PATHOLOGY; PROTEIN BINDING; T LYMPHOCYTE; TUMOR CELL LINE;

4-1BB LIGAND; ANTIGENS, CD137; ANTIGENS, CD80; ANTIGENS, CD86; CELL COMMUNICATION; CELL LINE; CELL LINE, TUMOR; CELLS, CULTURED; CULTURE; CYTOTOXICITY TESTS, IMMUNOLOGIC; CYTOTOXICITY, IMMUNOLOGIC; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULIN G; K562 CELLS; KILLER CELLS, NATURAL; NEOPLASMS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; OX40 LIGAND; PROTEIN BINDING; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; T-LYMPHOCYTES;

EID: 77956593114     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-07-234211     Document Type: Article

References (33)

1. Cerwenka A, Lanier LL. Natural killer cells, viruses and cancer. Nat Rev Immunol. 2001;1(1):41-49. (Pubitemid 33741974)
2. Lanier LL. NK cell recognition. Annu Rev Immunol. 2005;23:225-274.
3. Chapoval AI, Fuller JA, Kremlev SG, Kamdar SJ, Evans R. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells. J Immunol. 1998;161(12):6977-6984.
4. Alexander AZ, Maniar A, Cummings JS, et al. Isopentenyl pyrophosphate activated CD56+ γδ T lymphocytes display potent antitumor activity towards human squamous cell carcinoma. Clinical Cancer Research. 2008;14(13):4232-4240.
5. Ladel CH, Blum C, Kaufmann SH. Control of natural killer cell-mediated innate resistance against the intracellular pathogen Listeria monocytogenes by gamma/delta T lymphocytes. Infect Immun. 1996;64(5):1744-1749. (Pubitemid 26129835)
6. Hayday AC. [gamma][delta] cells: a right time and a right place for a conserved third way of protection. Annu Rev Immunol. 2000;18:975-1026.
7. Kabelitz D, Wesch D, He W. Perspectives of gammadelta T cells in tumor immunology. Cancer Res. 2007;67(1):5-8.
8. Hebbeler AM, Cairo C, Cummings JS, Pauza CD. Individual Vgamma2-Jgamma1.2+ T cells respond to both isopentenyl pyrophosphate and Daudi cell stimulation: generating tumor effectors with low molecular weight phosphoantigens. Cancer Immunol Immunother. 2007;56(6):819-829.
9. Dieli F, Vermijlen D, Fulfaro F, et al. Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res. 2007;67(15):7450-7457.
10. Wilhelm M, Kunzmann V, Eckstein S, et al. Gammadelta T cells for immune therapy of patients with lymphoid malignancies. Blood. 2003;102(1):200-206. (Pubitemid 36759655)
11. Kabelitz D, Wesch D, Pitters E, Zoller M. Characterization of tumor reactivity of human V gamma 9V delta 2 gamma delta T cells in vitro and in SCID mice in vivo. J Immunol. 2004;173(11):6767-6776.
12. Bank I, Book M, Huszar M, Baram Y, Schnirer I, Brenner H. V delta 2+ gamma delta T lymphocytes are cytotoxic to the MCF 7 breast carcinoma cell line and can be detected among the T cells that infiltrate breast tumors. Clin Immunol Immunopathol. 1993;67(1):17-24.
13. Corvaisier M, Moreau-Aubry A, Diez E, et al. V gamma 9V delta 2 T cell response to colon carcinoma cells. J Immunol. 2005;175(8):5481-5488. (Pubitemid 41456435)
14. Gao Y, Yang W, Pan M, et al. Gamma delta T cells provide an early source of interferon gamma in tumor immunity. J Exp Med. 2003;198(3):433-442.
15. Kobayashi H, Tanaka Y, Yagi J, et al. Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study. Cancer Immunol Immunother. 2006;56(4):469-476.
16. Shrestha N, Ida JA, Lubinski AS, Pallin M, Kaplan G, Haslett PA. Regulation of acquired immunity by gamma delta T-cell/dendritic-cell interactions. Ann N Y Acad Sci. 2005;1062:79-94.
17. Brandes M, Willimann K, Bioley G, et al. Cross-presenting human gammadelta T cells induce robust CD8+ alphabeta T cell responses. Proc Natl Acad Sci U S A. 2009;106(7):2307-2312.
18. Brandes M, Willimann K, Moser B. Professional antigen-presentation function by human gammadelta T Cells. Science. 2005;309(5732):264-268. (Pubitemid 40967855)
19. Zhang X, Voskens CJ, Sallin M, et al. CD137 promotes proliferation and survival of human B cells. J Immunol. 184(2):787-795.
20. Chapoval AI, Ni J, Lau JS, et al. B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol. 2001;2(3):269-274.
21. Taguchi Y, Kondo T, Watanabe M, et al. Interleukin-2-induced survival of natural killer (NK) cells involving phosphatidylinositol-3 kinase-dependent reduction of ceramide through acid sphingomyelinase, sphingomyelin synthase, and glucosylceramide synthase. Blood. 2004;104(10):3285-3293. (Pubitemid 39507147)
22. Lin W, Voskens CJ, Zhang X, et al. Fc-dependent expression of CD137 on human NK cells: insights into "agonistic" effects of anti-CD137 monoclonal antibodies. Blood. 2008;112(3):699-707.
23. Flies DB, Chen L. The new B7s: playing a pivotal role in tumor immunity. J Immunother. 2007;30(3):251-260.
24. Tamada K, Chen L. Renewed interest in cancer immunotherapy with the tumor necrosis factor superfamily molecules. Cancer Immunol Immunother. 2006;55(4):355-362. (Pubitemid 43076887)
25. Moretta A, Bottino C, Vitale M, et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol. 2001;19:197-223.
26. Kim YJ, Han MK, Broxmeyer HE. 4-1BB regulates NKG2D costimulation in human cord blood CD8+ T cells. Blood. 2008;111(3):1378-1386.
27. Martín-Fontecha A, Assarsson E, Carbone E, Karre K, Ljunggren HG. Triggering of murine NK cells by CD40 and CD86 (B7-2). J Immunol. 1999;162(10):5910-5916. (Pubitemid 29314945)
28. Wilson JL, Charo J, Martin-Fontecha A, et al. NK cell triggering by the human costimulatory molecules CD80 and CD86. J Immunol. 1999;163(8):4207-4212.
29. Ogasawara K, Yoshinaga SK, Lanier LL. Inducible costimulator costimulates cytotoxic activity and IFN-gamma production in activated murine NK cells. J Immunol. 2002;169(7):3676-3685.
30. Nausch N, Cerwenka A. NKG2D ligands in tumor immunity. Oncogene. 2008;27(45):5944-5958.
31. Taylor RJ, Chan SL, Wood A, et al. FcgammaRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck. Cancer Immunol Immunother. 2008;58(7):997-1006.
32. Pandya KJ, Gajra A, Warsi GM, Argonza-Aviles E, Ericson SG, Wozniak AJ. Multicenter, randomized, phase 2 study of zoledronic acid in combination with docetaxel and carboplatin in patients with unresectable stage IIIB or stage IV non-small cell lung cancer. Lung Cancer. 2010;67(3):330-338.
33. Kunzmann V, Bauer E, Wilhelm M. Gamma/delta T-cell stimulation by pamidronate. N Engl J Med. 1999;340(9):737-738.